Health Care & Life Sciences » Biotechnology | RedHill Biopharma Ltd.

RedHill Biopharma Ltd. ADR | Cash Flow

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
38,361.90
38,315.30
81,939.30
112,744.60
163,820.60
139,568.10
Depreciation, Depletion & Amortization
86.60
96.60
139.90
168.90
291.40
323.60
Other Funds
4,046.30
6,478.30
2,552.60
1,977.00
10,683.00
10,242.90
Funds from Operations
34,229.00
31,740.40
79,246.80
110,598.70
174,212.30
129,001.60
Changes in Working Capital
3,779.20
12,005.10
9,988.90
2,122.80
13,179.30
5,101.70
Net Operating Cash Flow
30,449.80
43,745.50
69,257.90
108,475.90
161,033.00
123,900
Capital Expenditures
808.50
3,952.80
6,348.40
460.70
4,248.00
Purchase/Sale of Investments
4,883.70
59,943.00
75,987.10
94,402.90
62,591.00
Net Investing Cash Flow
4,075.10
63,895.80
82,335.60
93,942.30
66,839.00
Net Financing Cash Flow
8,229.70
87,172.60
212,878.90
138,260.80
92,273.20
Net Change in Cash
17,914.00
21,316.50
60,702.70
123,877.00
134,278.70
Free Cash Flow
30,500.30
43,995.90
69,312.30
108,802.20
161,558.10
Change in Capital Stock
8,229.70
87,172.60
212,878.90
138,260.80
92,273.20
Exchange Rate Effect
231.00
847.80
582.80
149.70
1,320.10

About RedHill Biopharma

View Profile
Address
21 Ha'arba'a Street
Tel Aviv TA 64739
Israel
Employees -
Website http://www.redhillbio.com
Updated 07/08/2019
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. Its late clinical-stage pipeline includes TALICIA® (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria (NTM) infections; BEKINDA® (RHB-102) for acute gastroenteritis and gastritis and IBS-D; YELIVA® (ABC294640) for cholangiocarcinoma and targeting multiple other oncology, inflammatory and gastrointestinal indications; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and RHB-107, targeting cancer and inflammatory gastrointestinal diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.